New research has confirmed the accuracy of the novel European Association of Urology (EAU) risk classification system that groups prostate cancer patients based on their risk of recurrence.
Category: Nuclear Medicine
The effects of COVID-19 on the brain can be accurately measured with PET, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.Read More
PET using a 68Ga-labeled fibroblast activation protein inhibitor can noninvasively identify and monitor pulmonary fibrosis, according to new research.Read More
A new imaging technique has the potential to detect neurological disorders—such as Alzheimer’s disease—at their earliest stages, enabling physicians to diagnose and treat patients more quickly.Read More
Canon Medical’s Digital PET/CT System Receives FDA Clearance for AI-Based Image Reconstruction Technology
Bringing the capabilities of artificial intelligence to molecular imaging, Advanced intelligent Clear-IQ Engine, Canon Medical Systems USA Inc.’s Deep Learning Reconstruction technology, is now U.S. FDA 510(k) cleared on the Cartesion Prime Digital PET/CT system.Read More
The targeted radionuclide therapy 177Lu-PSMA-617 has been proven effective in improving survival in men with advanced prostate cancer, according to recently published results from the VISION trial.Read More